Xtant Medical Holdings, Inc.
AMEX:XTNTMedical - Devices
-$0.00 today
- Market cap
- $50.37M
- Beta
- -0.17
- P/E (TTM)
- 33.4
- EPS (TTM)
- $0.01
Volume 0.16M
Average 0.16M
XTNT Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Xtant Medical Holdings, Inc.AMEX: XTNT
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income turns negative
Q1 FY2026 net income was -$3.09M, compared with $58K a year earlier. Trailing-twelve-month net income was $1.83M.
Context
- Net income amounted to 3.7% of revenue in FY2025, down 10.3 pp from a year earlier.
- Net income increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 3 analysts of -$3.74M (-175.3%) for the fiscal year ending Dec 2026, a slowdown from the +130.2% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$3.09M-5519.3% QoQ
- Last fiscal yearDec 2025
- $4.97M+130.2% YoY
- LTMMar 2026
- $1.83M+115.2% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -5425.9% | -179.0% | +5246.8 pp |
| 1 year | +130.2% | -175.3% | -305.5 pp |
| 3-year CAGR | — | -23.2% | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- 4.97M USD
- Year-over-year change
- +130.2%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 4.97M | +130.2% |
| FY2024 | 2024-12-31 | (16.45M) | -2592.3% |
| FY2023 | 2023-12-31 | 660K | +107.8% |
| FY2022 | 2022-12-31 | (8.49M) | -75.0% |
| FY2021 | 2021-12-31 | (4.85M) | — |
Net Income vs competitors
How XTNT compares with its peers on the latest reported figures
- XTNT's LTM Mar 2026 net income of $1.83M is the smallest of the 8 companies compared; the peer median is $27.09M.
- Its year-over-year change of +115.2% is the 2nd highest of 8, against a peer median of +11.8%.
- Net income amounts to 1.5% of revenue for XTNT, versus a peer median of 62.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $26.68B | +43056.2% | +1.1% | 519699.0% | |
| LTM Mar 2026 | $50.14M | +11.8% | -8.1% | 145.8% | |
| LTM Mar 2026 | $45.34M | -20.5% | +22.1% | 62.7% | |
| LTM Mar 2026 | $27.09M | +14.1% | +24.2% | — | |
EXOZeXoZymes, Inc. | LTM Mar 2026 | $9.67M | +44.2% | +87.2% | — |
| LTM Mar 2026 | $9.05M | -55.1% | -21.9% | 16.2% | |
| LTM Mar 2026 | $8.27M | -11.1% | -14.8% | 7.8% | |
| LTM Mar 2026 | $1.83M | +115.2% | — | 1.5% | |
| Peer median (excluding XTNT) | $27.09M | +11.8% | +1.1% | 62.7% | |
Competitors are the stored peer set for XTNT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (4.85M) | (8.49M) | 660K | (16.45M) | 4.97M |
| Depreciation & Amortization | 1.33M | 1.29M | 3.17M | 4.22M | 5.22M |
| Deferred Income Tax | 0 | 0 | (1.9M) | 21K | 0 |
| Stock-Based Compensation | 2.21M | 2.46M | 2.74M | 4.12M | 2.89M |
| Change in Working Capital | 793K | (2.81M) | (3.63M) | (5.35M) | (3.05M) |
| Accounts Receivables | (319K) | (3.94M) | (8.74M) | (755K) | (591K) |
| Inventory | 2.62M | (1.15M) | (1.89M) | (2.49M) | (2M) |
| Accounts Payables | (332K) | 875K | 2.98M | 1.03M | (3.12M) |
| Other Working Capital | (1.18M) | 1.41M | 4.01M | (3.13M) | 2.66M |
| Other Non-Cash Items | 954K | 2.2M | (10.55M) | 1.54M | 2.5M |
| Operating Cash Flow | 439K | (5.34M) | (9.52M) | (11.9M) | 12.55M |
| Capital Expenditures | (2.12M) | (1.76M) | (1.46M) | (4.11M) | (2.38M) |
| Acquisitions (Net) | 0 | 0 | (23.5M) | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 225K | 205K | 175K | 383K | 10.28M |
| Investing Cash Flow | (1.89M) | (1.56M) | (24.78M) | (3.73M) | 7.9M |
| Debt Repayment | (592K) | (291K) | 6.18M | 12.43M | (9.33M) |
| Common Stock Issued | 18.43M | 9.31M | 14.01M | 4.46M | 0 |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | (65K) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (337K) | 9.07M | (500K) | (816K) | (175K) |
| Financing Cash Flow | 17.5M | 9.02M | 19.69M | 16.07M | (9.57M) |
| Effect of Forex Changes | 0 | 0 | 24K | (149K) | 232K |
| Net Change in Cash | 16.05M | 2.12M | (14.58M) | 298K | 11.11M |
| Free Cash Flow | (1.68M) | (7.11M) | (10.97M) | (16.01M) | 10.16M |
Xtant Medical Holdings, Inc.
AMEX:XTNT
Intrinsic Alpha fair value
Locked
Current Price
$0.36
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.